Research

Researcher setting up genetic samples and primers for polymerase chain reaction

Parkinson's Disease and other movement disorders

Hope through research

The USF Health Byrd Parkinson's Disease & Movement Disorders Center evaluates and develops new medications and surgical procedures for Parkinson's Disease. Under Dr. Hauser's leadership, we conduct multiple independent and sponsored studies, pioneering advancements in treatment through research and innovation.

PPMI

 

Brief summary: Take the Smell Test Challenge Today!   Smell loss can be linked to brain disease.  Researchers are studying this link to learn more about the connection. Not everyone with smell loss will develop a brain disease.  Request a scratch-and-sniff test to help scientists learn more about this risk factor.

Status: Recruiting (by cohort - contact our Center for details ) - To request a free smell test, visit:

https://mysmelltest.org/sf01

 

Illustration of images of genes (red, green and blue spots) are superimposed on images of multi-well plates

Neuron23

NEU-411-PD201

Brief summary: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of NEU-411 in Companion Diagnostic-Positive Participants with Early Parkinson's Disease (NEULARK)

Status: Recruiting

https://clinicaltrials.gov/study/NCT06680830?titles=NEULARK&rank=1

 

microscope

Padova

ID: NCT04777331

Brief summary: A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease (PADOVA)

Status: Active, not recruiting

https://clinicaltrials.gov/study/NCT04777331?tab=results

 

M20-098

ID: NCT04750226

Brief summary: Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease

Status: Maintaining

https://clinicaltrials.gov/study/NCT04750226?rank=1

Human breast cancer cells

LUMA

ID: NCT05348785

Brief summary: A Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early-Stage Parkinson's Disease in Participants Between the Ages of 30 and 80 (LUMA)

Status: Maintaining

https://clinicaltrials.gov/study/NCT05348785

 

Pasadena

ID: NCT03100149

Brief summary: This multicenter, randomized, double-blind, placebo-controlled, Phase 2 study will evaluate the efficacy of intravenous prasinezumab (RO7046015/PRX002) versus placebo over 52 weeks in participants with early Parkinson's Disease (PD) who are untreated or treated with monoamine oxidase B (MAO-B) inhibitors since baseline. 

Status: Maintaining

https://clinicaltrials.gov/study/NCT03100149

Cerevance

CVN424-301

Brief summary: A study to assess the efficacy of CVN424 dosed once daily, compared to placebo, for change in OFF time in Parkinson’s Disease.

Status: Enrolling

https://clinicaltrials.gov/study/NCT06553027

TEVA - Topas MSA

TV56286-NDG-20039

Brief summary: A study to assess the safety and efficacy of TEV-56286 in adult patients with MSA, relative to a placebo, over a period of 48 weeks

Status: Enrolling

https://clinicaltrials.gov/study/NCT05923866

Support

Our clinical trials enable us to innovate and discover new, effective treatments for Parkinson's disease and other movement disorders. The importance of our work cannot be overstated, as it brings us closer to a cure and improves the quality of life for countless patients. Donations are crucial to sustaining this vital research and ensuring ongoing progress.

 

To support our mission, click here or reach out to Ashley Messer at amesser2@usf.edu or (813) 389-2845.